Peixin Amy Chen

Peixin Amy Chen

Auto-generated profile, based on publicly available information

Peixin Amy Chen

Department of Medicine, University of California San Francisco, San Francisco, CA USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CCCarole Le Coz
Carole Le Coz
DNDavid N. Nguyen
David N. Nguyen
CSChun Su
Chun Su
BNBrian E. Nolan
Brian E. Nolan
AAAmanda V. Albrecht
Amanda V. Albrecht
NRNeil Romberg
Neil Romberg
The pioneer transcription factor (TF) PU.1 controls hematopoietic cell fate by decompacting stem cell heterochromatin and allowing nonpioneer TFs to enter otherwise inaccessible genomic sites. PU.1 deficiency fatally arrests lymphopoiesis and myelopoiesis in mice, but human congenital PU.1 disorders have not previously been described. We studied six unrelated agammaglobulinemic patients, each harboring a heterozygous mutation (four de novo, two unphased) of SPI1, the gene encoding PU.1. Affected patients lacked circulating B cells and possessed few conventional dendritic cells. Introducing disease-similar SPI1 mutations into human hematopoietic stem and progenitor cells impaired early in vitro B cell and myeloid cell differentiation. Patient SPI1 mutations encoded destabilized PU.1 proteins unable to nuclear localize or bind target DNA. In PU.1-haploinsufficient pro–B cell lines, euchromatin was less accessible to nonpioneer TFs critical for B cell development, and gene expression patterns associated with the pro– to pre–B cell transition were undermined. Our findings molecularly describe a novel form of agammaglobulinemia and underscore PU.1’s critical, dose-dependent role as a hematopoietic euchromatin gatekeeper.

15 September 2023 in Cell
Verified
Journal Article
Open access
FBFranziska Blaeschke
Franziska Blaeschke
YCYan Yi Chen
Yan Yi Chen
RARyan Apathy
Ryan Apathy
BDBence Daniel
Bence Daniel
ACAndy Y. Chen
Andy Y. Chen
AMAlex Marson
Alex Marson
Chronic stimulation can cause T cell dysfunction and limit the efficacy of cellular immunotherapies. Improved methods are required to compare large numbers of synthetic knockin (KI) sequences to reprogram cell functions. Here, we developed modular pooled KI screening (ModPoKI), an adaptable platform for modular construction of DNA KI libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors (SRs). Over 30 ModPoKI screens across human TCR- and CAR-T cells in diverse conditions identified a transcription factor AP4 (TFAP4) construct that enhanced fitness of chronically stimulated CAR-T cells and anti-cancer function in vitro and in vivo. ModPoKI's modularity allowed us to generate an ∼10,000-member library of TF combinations. Non-viral KI of a combined BATF-TFAP4 polycistronic construct enhanced fitness. Overexpressed BATF and TFAP4 co-occupy and regulate key gene targets to reprogram T cell function. ModPoKI facilitates the discovery of complex gene constructs to program cellular functions.

12 November 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
SBStefanie Bachl
Stefanie Bachl
CCCarter Ching
Carter Ching
ATAlexis Talbot
Alexis Talbot
AFAntoine Forget
Antoine Forget
NKNupura Kale
Nupura Kale
JCJulia Carnevale
Julia Carnevale
Engineered T-cell therapies are limited by progressive dysfunction under chronic tumor antigen exposure, and genetic perturbation of negative regulators has emerged as a promising strategy to sustain effector activity. We reanalyzed a genome-wide CRISPR knockout (KO) screen in primary human T cells under repetitive tumor stimulation; protein–protein interaction mapping revealed seven members of the cullin–RING ligase 5 (CRL5) complex as an enriched hit cluster. KO of any of these members [cullin-5 (CUL5), ARIH2, RNF7, UBE2F, UBE2L3, CISH, and DCUN1D3] enhanced tumor serial killing, and CUL5, the complex scaffold, emerged as the strongest target. CUL5 KO T cells exhibited sustained cytotoxicity, elevated effector cytokine production, and fewer exhaustion marker–positive cells while retaining antigen specificity and cytokine dependence. Quantitative ubiquitylation proteomics in resting and acutely and chronically stimulated T cells mapped CRL5-dependent candidate substrates beyond the canonical JAK/STAT axis, including nutrient transporters, receptor trafficking proteins, and T-cell receptor (TCR) signaling components. The benefit of CUL5 KO extended across chimeric antigen receptor (CAR) targeting CD19, B-cell maturation antigen (BCMA), and human epidermal growth factor receptor 2 (HER2) with different costimulatory domains and to 1XX-modified CAR and human leukocyte antigen–independent TCR architectures. Combining CUL5 ablation with a tumor-induced IL2 circuit produced tumor control across nine rounds of repetitive stimulation, whereas either modification alone eventually failed. In vivo, CUL5 KO BCMA CAR T cells were enriched in the bone marrow following repeated tumor rechallenge and exhibited enhanced ex vivo cytotoxicity after nearly 90 days in tumor-bearing mice. These findings position CUL5 perturbation as a strategy to improve T-cell persistence and the efficacy of adoptive cell therapies, potentially with engineered cytokine support. Significance: Knockout of CLR5 complex members, especially CUL5, attenuates T-cell exhaustion during prolonged tumor exposure, enabling CAR- and TCR-engineered T cells to sustain cytotoxicity during repeated tumor challenge. See related commentary by Hanina and Maus, p. XX . See related article by Saco et al., p. XX .

29 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
YRYvonne Rong
Yvonne Rong
MVMikhail Vysotskiy
Mikhail Vysotskiy
PCPeixin Amy Chen
Peixin Amy Chen
EAEkansh Agrawal
Ekansh Agrawal
EMEdward Marsh
Edward Marsh
DNDavid N. Nguyen
David N. Nguyen
Distinguishing pathogenic from benign mutation is critical for genetic diagnosis. A CRISPR-targeted saturation genome editing (SGE) platform in primary human cells assessed 489 single nucleotide variants (SNVs) in exon 5 of IL2RG, the gene causing X-linked SCID. The functional impact was clearly defined for 470 variants, agreeing with 100% (18/18) of ClinVar-deposited benign or likely benign annotations, and 100% (42/42) of pathogenic or likely pathogenic annotations. We discovered 90 novel loss-of-function mutations and validated an expected block in T-lymphocyte differentiation from edited hematopoietic stem cells.